Exome Asset Management LLC: CYTOKINETICS INC (CYTK): Quarterly 13F Position History
As of Q1 2026, Exome Asset Management LLC reported 103,718 shares of CYTOKINETICS INC (CYTK), worth $6.8M and representing 4.0% of its 13F equity book. Quarter-over-quarter share count change: 21,031 (-16.9%) . The position first appeared in Q4 2023 and has been disclosed across 10 13F-HR filings in Pactolio's tracked window.
- 103,718Shares Held (Latest Filing)
- $6.8MReported Market Value (Latest Filing)
- 4.0%Portfolio Weight (% of 13F Equity Book)
- 21,031Quarter-over-Quarter Share Change
- -$1.1MQuarter-over-Quarter Value Change
- 142,417Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 10 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 103,718 | 21,031 | -16.9% | $6.8M | 4.0% | $65.9 |
| Q4 2025 | 124,749 | 17,668 | -12.4% | $7.9M | 3.9% | $63.5 |
| Q3 2025 | 142,417 | +26,600 | +23.0% | $7.8M | 5.2% | $55.0 |
| Q2 2025 | 115,817 | +12,334 | +11.9% | $3.8M | 3.1% | $33.0 |
| Q1 2025 | 103,483 | +37,600 | +57.1% | $4.2M | 3.7% | $40.2 |
| Q4 2024 | 65,883 | +7,300 | +12.5% | $3.1M | 2.3% | $47.0 |
| Q3 2024 | 58,583 | +58,583 | — | $3.1M | 2.1% | $52.8 |
| Q2 2024 | 0 | 26,008 | -100.0% | $0 | 0.0% | — |
| Q1 2024 | 26,008 | 8,900 | -25.5% | $1.8M | 1.6% | $70.1 |
| Q4 2023 | 34,908 | — | — | $2.9M | 2.9% | $83.5 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Exome Asset Management LLC first disclose a CYTK position in 13F-HR filings?
Exome Asset Management LLC first reported CYTOKINETICS INC (CYTK) on its 13F-HR filing for the period ending 2023-12-31 (Q4 2023). The position has appeared on 10 reported quarters within Pactolio's tracked window.
What was Exome Asset Management LLC's most recent quarter-over-quarter share-count change in CYTK?
Between Q4 2025 and Q1 2026, Exome Asset Management LLC reduced its CYTK position by 21,031 shares (-16.9%), leaving 103,718 shares at a market value of $6.8M.
Does the implied price-per-share represent Exome Asset Management LLC's cost basis in CYTK?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.